Medtech company MedAlliance acquired by Cordis for USD 1.135 billion. Table of ContentsMedAlliance DEB technologyCordis GENEVA, Oct. 2, 2023 – Swiss-based medical technology comp… Read More

GENEVA, Jan. 11, 2023 /PRNewswire/ — SELUTION SLR, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approva… Read More

GENEVA, Switzerland, Sept. 10, 2022 /PRNewswire/ — An 82-year-old Taiwanese man has become the first patient to be enrolled in the initial Erectile Dysfunction (ED) randomized clinical… Read More

GENEVA, Switzerland, Aug. 24, 2022 /PRNewswire/ — The first US patient has been enrolled in the FDA SELUTION4BTK (Below-the-Knee) clinical trial evaluating SELUTION SLR, MedAllian… Read More

GENEVA, Oct. 19, 2022 /PRNewswire/ — Swiss-based medical technology company MedAlliance has announced it has entered into an agreement with Cordis for an acquisition which include… Read More

Genf (ots/PRNewswire) – Die MedAlliance freut sich, die Aufnahme des ersten Patienten in die bahnbrechende koronare randomisiert-kontrollierte Studie “SELUTION DeNovo” b… Read More